Mitchell G Miglis, Charles H Adler, Elena Antelmi, Dario Arnaldi, Luca Baldelli, Bradley F Boeve, Matteo Cesari, Irene Dall'Antonia, Nico J Diederich, Kathrin Doppler, Petr Dušek, Raffaele Ferri, Jean-François Gagnon, Ziv Gan-Or, Wiebke Hermann, Birgit Högl, Michele T Hu, Alex Iranzo, Annette Janzen, Anastasia Kuzkina, Jee-Young Lee, Klaus L Leenders, Simon J G Lewis, Claudio Liguori, Jun Liu, Christine Lo, Kaylena A Ehgoetz Martens, Jiri Nepozitek, Giuseppe Plazzi, Federica Provini, Monica Puligheddu, Michal Rolinski, Jan Rusz, Ambra Stefani, Rebekah L S Summers, Dallah Yoo, Jennifer Zitser, Wolfgang H Oertel,
Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and ... Read more >>
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):671-684]
Cited: 0 times
Hannah K Warming, Erin M Schuman, Arpan R Mehta,
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):602]
Cited: 0 times
Benjamin Maïer, Jean-Philippe Desilles, Mikael Mazighi, ,
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):595-596]
Cited: 0 times
Giovanni B Frisoni, Oskar Hansson,
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):586-587]
Cited: 0 times
Anne M Fagan, Rachel L Henson, Yan Li, Anna H Boerwinkle, Chengjie Xiong, Randall J Bateman, Alison Goate, Beau M Ances, Eric Doran, Bradley T Christian, Florence Lai, H Diana Rosas, Nicole Schupf, Sharon Krinsky-McHale, Wayne Silverman, Joseph H Lee, William E Klunk, Benjamin L Handen, Ricardo F Allegri, Jasmeer P Chhatwal, Gregory S Day, Neill R Graff-Radford, Mathias Jucker, Johannes Levin, Ralph N Martins, Colin L Masters, Hiroshi Mori, Catherine J Mummery, Yoshiki Niimi, John M Ringman, Stephen Salloway, Peter R Schofield, Mikio Shoji, Ira T Lott, , ,
<h4>Background</h4>Due to trisomy of chromosome 21 and the resultant extra copy of the amyloid precursor protein gene, nearly all adults with Down syndrome develop Alzheimer's disease pathology by the age of 40 years and are at high risk for dementia given their increased life expectancy compared with adults with Down ... Read more >>
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):615-626]
Cited: 0 times
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):599-600]
Cited: 0 times
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):589-591]
Cited: 0 times
Eveline Janine Anna Wiegers, Hester Floor Lingsma, Jilske Antonia Huijben, David James Cooper, Giuseppe Citerio, Shirin Frisvold, Raimund Helbok, Andrew Ian Ramsay Maas, David Krishna Menon, Elizabeth Madeleine Moore, Nino Stocchetti, Diederik Willem Dippel, Ewout Willem Steyerberg, Mathieu van der Jagt, , ,
<h4>Background</h4>Fluid therapy-the administration of fluids to maintain adequate organ tissue perfusion and oxygenation-is essential in patients admitted to the intensive care unit (ICU) with traumatic brain injury. We aimed to quantify the variability in fluid management policies in patients with traumatic brain injury and to study the effect of this ... Read more >>
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):627-638]
Cited: 0 times
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):601]
Cited: 0 times
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):591-592]
Cited: 0 times
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):e5]
Cited: 0 times
Maria Carmona-Iragui, Daniel Alcolea, Isabel Barroeta, Laura Videla, Laia Muñoz, Kathyrn L Van Pelt, Frederick A Schmitt, Donita D Lightner, Lisa M Koehl, Gregory Jicha, Silvia Sacco, Clotilde Mircher, Sarah E Pape, Rosalyn Hithersay, Isabel C H Clare, Anthony J Holland, Georg Nübling, Johannes Levin, Shahid H Zaman, Andre Strydom, Anne-Sophie Rebillat, Elizabeth Head, Rafael Blesa, Alberto Lleó, Juan Fortea,
<h4>Background</h4>Adults with Down syndrome are at an ultra-high risk of Alzheimer's disease, but diagnosis of Alzheimer's disease in this population is challenging. We aimed to validate the clinical utility of plasma neurofilament light chain (NfL) for the diagnosis of symptomatic Alzheimer's disease in Down syndrome, assess its prognostic value, and ... Read more >>
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):605-614]
Cited: 0 times
Mayank Goyal, Johanna Maria Ospel, Andrew Demchuk, Rosalie Victoria McDonough,
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):595]
Cited: 0 times
Patrick M Kochanek, Ruchira M Jha,
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):587-589]
Cited: 0 times
Irene Cortese, Erin S Beck, Omar Al-Louzi, Joan Ohayon, Frances Andrada, Ikesinachi Osuorah, Jenifer Dwyer, B Jeanne Billioux, Nigar Dargah-Zada, Matthew K Schindler, Kyle Binder, Lauren Reoma, Gina Norato, Yoshimi Enose-Akahata, Bryan R Smith, Maria Chiara Monaco, Eugene O Major, Steven Jacobson, David Stroncek, Steven Highfill, Sandhya Panch, Daniel S Reich, John Barrett, Avindra Nath, Pawel Muranski,
<h4>Background</h4>Progressive multifocal leukoencephalopathy, a rare disease of the CNS caused by JC virus and occurring in immunosuppressed people, is typically fatal unless adaptive immunity is restored. JC virus is a member of the human polyomavirus family and is closely related to the BK virus. We hypothesised that use of partly ... Read more >>
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):639-652]
Cited: 0 times
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):602]
Cited: 0 times
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):593-594]
Cited: 0 times
The Lancet Neurology,
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):585]
Cited: 0 times
Steven M Greenberg, Charlotte Cordonnier, Julie A Schneider, Eric E Smith, Mark A van Buchem, Susanne J van Veluw, Marcel M Verbeek, Anand Viswanathan, David J Werring,
Lancet Neurol (The Lancet. Neurology)
[2021, 20(8):596-597]
Cited: 0 times
Nirosen Vijiaratnam, Tanya Simuni, Oliver Bandmann, Huw R Morris, Thomas Foltynie,
The development of interventions to slow or halt the progression of Parkinson's disease remains a priority for patients and researchers alike. To date, no agents have been shown to have unequivocal evidence of disease-modifying effects in Parkinson's disease. The absence of disease-modifying treatments might relate not only to inadequate approaches ... Read more >>
Lancet Neurol (The Lancet. Neurology)
[2021, 20(7):559-572]
Cited: 0 times
James Pratt, Evan Lester, Roy Parker,
Lancet Neurol (The Lancet. Neurology)
[2021, 20(7):506]
Cited: 0 times
Raquel Sánchez-Valle,
Lancet Neurol (The Lancet. Neurology)
[2021, 20(7):500-502]
Cited: 0 times
James F Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Temur Margania, Hiroyuki Murai, Malgorzata Bilinska, Roman Shakarishvili, Marek Smilowski, Antonio Guglietta, Peter Ulrichts, Tony Vangeneugden, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza, ,
<h4>Background</h4>There is an unmet need for treatment options for generalised myasthenia gravis that are effective, targeted, well tolerated, and can be used in a broad population of patients. We aimed to assess the safety and efficacy of efgartigimod (ARGX-113), a human IgG1 antibody Fc fragment engineered to reduce pathogenic IgG ... Read more >>
Lancet Neurol (The Lancet. Neurology)
[2021, 20(7):526-536]
Cited: 0 times
Karl Deisseroth, Jane E Haley, Arpan R Mehta,
Lancet Neurol (The Lancet. Neurology)
[2021, 20(7):508]
Cited: 0 times
Martijne H C Duvekot, Esmee Venema, Henk Kerkhoff, Diederik W J Dippel, Bob Roozenbeek,
Lancet Neurol (The Lancet. Neurology)
[2021, 20(7):504-505]
Cited: 0 times